Instil Bio, Inc. Comprehensive Income
Instil Bio, Inc. (TIL) reported Comprehensive Income of -$4.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Instil Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$4.35M.
- Instil Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$4.15M.
- Instil Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$8.16M.
- Instil Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$13.39M.
- Instil Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$71.73M.
- Instil Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$74.02M.
- Instil Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$155.94M.
- Instil Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$223.58M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.35M 10-Q · filed 2026-08-13 | -$8.51M 10-Q · filed 2026-08-13 | -$16.67M derived: sum of 3 quarters · filed 2026-08-13 | -$30.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$4.15M 10-Q · filed 2026-05-15 | -$12.31M derived: sum of 2 quarters · filed 2026-05-15 | -$25.71M derived: sum of 3 quarters · filed 2026-05-15 | -$47.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$8.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$21.56M derived: sum of 2 quarters · filed 2026-03-27 | -$43.30M derived: sum of 3 quarters · filed 2026-08-13 | -$71.73M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$13.39M 10-Q · filed 2025-11-13 | -$35.14M derived: sum of 2 quarters · filed 2026-08-13 | -$63.56M 10-Q · filed 2025-11-13 | -$75.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$21.75M 10-Q · filed 2026-08-13 | -$50.17M 10-Q · filed 2026-08-13 | -$61.77M derived: sum of 3 quarters · filed 2026-08-13 | -$84.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$28.42M 10-Q · filed 2026-05-15 | -$40.03M derived: sum of 2 quarters · filed 2026-05-15 | -$62.94M derived: sum of 3 quarters · filed 2026-05-15 | -$77.92M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$34.52M derived: sum of 2 quarters · filed 2026-03-27 | -$49.50M derived: sum of 3 quarters · filed 2026-03-27 | -$74.02M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$22.91M 10-Q · filed 2025-11-13 | -$37.90M derived: sum of 2 quarters · filed 2025-11-13 | -$62.41M 10-Q · filed 2025-11-13 | -$75.16M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$14.98M 10-Q · filed 2025-08-13 | -$39.50M 10-Q · filed 2025-08-13 | -$52.25M derived: sum of 3 quarters · filed 2025-08-13 | -$119.41M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$24.52M 10-Q · filed 2025-05-13 | -$37.27M derived: sum of 2 quarters · filed 2025-05-13 | -$104.43M derived: sum of 3 quarters · filed 2025-05-13 | -$123.48M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$79.91M derived: sum of 2 quarters · filed 2025-03-04 | -$98.96M derived: sum of 3 quarters · filed 2025-03-04 | -$155.94M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$67.16M 10-Q · filed 2024-11-13 | -$86.21M derived: sum of 2 quarters · filed 2024-11-13 | -$143.19M 10-Q · filed 2024-11-13 | -$197.20M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$19.05M 10-Q · filed 2024-08-13 | -$76.03M 10-Q · filed 2024-08-13 | -$130.03M derived: sum of 3 quarters · filed 2024-08-13 | -$186.04M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$56.98M 10-Q · filed 2024-05-10 | -$110.98M derived: sum of 2 quarters · filed 2024-05-10 | -$166.99M derived: sum of 3 quarters · filed 2024-05-10 | -$226.09M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$54.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$110.00M derived: sum of 2 quarters · filed 2024-03-21 | -$169.11M derived: sum of 3 quarters · filed 2024-03-21 | -$223.58M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$56.00M 10-Q · filed 2023-11-13 | -$115.11M derived: sum of 2 quarters · filed 2023-11-13 | -$169.58M 10-Q · filed 2023-11-13 | -$224.91M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$59.11M 10-Q · filed 2023-08-14 | -$113.58M 10-Q · filed 2023-08-14 | -$168.91M derived: sum of 3 quarters · filed 2023-08-14 | -$211.81M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$54.47M 10-Q · filed 2023-05-11 | -$109.80M derived: sum of 2 quarters · filed 2023-05-11 | -$152.70M derived: sum of 3 quarters · filed 2023-05-11 | -$187.97M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$55.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$98.23M derived: sum of 2 quarters · filed 2023-03-31 | -$133.50M derived: sum of 3 quarters · filed 2023-03-31 | -$156.60M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$42.90M 10-Q · filed 2022-11-14 | -$78.17M derived: sum of 2 quarters · filed 2022-11-14 | -$101.27M 10-Q · filed 2022-11-14 | -$118.72M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$35.27M 10-Q · filed 2022-08-12 | -$58.37M 10-Q · filed 2022-08-12 | -$75.82M derived: sum of 3 quarters · filed 2022-08-12 | -$83.06M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$23.10M 10-Q · filed 2022-05-16 | -$40.55M derived: sum of 2 quarters · filed 2022-05-16 | -$47.80M derived: sum of 3 quarters · filed 2022-05-16 | -$57.00M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$17.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$24.70M derived: sum of 2 quarters · filed 2022-03-07 | -$33.90M derived: sum of 3 quarters · filed 2022-03-07 | -$38.02M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$7.25M 10-Q · filed 2021-11-15 | -$16.44M derived: sum of 2 quarters · filed 2021-11-15 | -$20.57M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$9.20M 10-Q · filed 2021-08-12 | -$13.32M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$4.12M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |